Boston Scientific Corporation (NYSE:BSX) Short Interest Up 74.4% in August

Boston Scientific Corporation (NYSE:BSX) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 48,173,758 shares, a growth of 74.4% from the August 15th total of 27,617,554 shares. Approximately 3.3% of the company’s shares are sold short. Based on an average daily volume of 21,036,931 shares, the days-to-cover ratio is currently 2.3 days.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 194,522 shares of company stock valued at $9,385,210 over the last 90 days. 0.34% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently bought and sold shares of the business. State Street Corp increased its holdings in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the period. BlackRock Inc. acquired a new position in Boston Scientific in the 2nd quarter valued at $5,534,781,000. Capital World Investors lifted its position in shares of Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after acquiring an additional 502,627 shares during the period. Norges Bank acquired a new stake in shares of Boston Scientific during the 4th quarter worth $2,199,395,000. Finally, Primecap Management Co. CA bought a new position in shares of Boston Scientific in the second quarter worth $2,156,233,000. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Royal Bank Of Canada dropped their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, July 30th. Canaccord Genuity Group decreased their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Stifel Nicolaus set a $60.00 price objective on shares of Boston Scientific in a research report on Wednesday, July 29th. Finally, Needham & Company LLC dropped their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Twenty-three research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $71.04.

Boston Scientific Stock Performance

Shares of BSX stock opened at $43.42 on Friday. The company has a market capitalization of $62.93 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 1.02 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific has a 52 week low of $42.20 and a 52 week high of $105.65. The company has a 50-day simple moving average of $46.93 and a 200 day simple moving average of $53.64.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts predict that Boston Scientific will post 3.29 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.